Table 1.
Patient cohort.
| Number of patients, n (%) | 69 (100) | ||
| Adult cases | 47 (68.1) | ||
| Elderly (≥60 y) | 25 (36.2) | ||
| Adult (40–59 y) | 16 (23.2) | ||
| Young adult (19–39 y) | 6 (8.7) | ||
| Pediatric cases | 22 (31.9) | ||
| Adolescent (15–18 y) | 2 (2.9) | ||
| Child (3–14 y) | 13 (18.8) | ||
| Infant (<3 y) | 7 (10.1) | ||
| Sex, female | 37 (53.6) | ||
| Background | de novo AML | 62 (89.9) | |
| Potential t-AML | 3 (4.3) | ||
| MDS-AML | 2 (2.9) | ||
| t-MDS-AML | 2 (2.9) | ||
| Number of tumor samples, n (%) | 119 (100) | ||
| Diagnosis samples | 42 (35.3) | ||
| Relapse samples | 71 (59.7) | ||
| R1 and R1-P | 56 (47.1) | ||
| R2 and R2-P | 12 (10.1) | ||
| R3 | 3 (2.5) | ||
| Primary resistant samples | 6 (5.0) | ||
| Mean age at onset (y) | Adult cases | 59.5 (median: 62.2; range: 20.5–83.1) | |
| Pediatric cases | 7.7 (median: 7.3; range: 0.4–17.5) | ||
| Mean length of EFS (m; D > R1) | Adult relapse cases | 16.3 (median: 10.0; range: 1.1–126.0) | |
| Pediatric relapse cases | 9.9 (median: 9.9; range: 2.3–19.1) | ||
| Mean length of OS (m) | Adult relapse cases | 39.9 (median: 21.0; range: 1.5–271.1) | |
| Pediatric relapse cases | 52.9 (median: 18.8; range: 5.6–215.0) | ||
| Sampling duration | 1995–2016 | ||
Detailed biological and clinical data for each patient/sample are presented in Supplementary Tables 1 and 2.
D Diagnosis, EFS event-free survival as time to first relapse, MDS Myelodysplastic syndromes, OS Overall survival, R1/2/3 Sequential relapses, R1/2-P Persistent relapse specimen, t-AML Treatment related AML.